Quantitively Differentiating Cardiac from Non-Cardiac related Chest Pain

heart-attack

Early diagnosis and treatment of myocardial infarction can save patients life and prevent life-threatening complications AS reducing the time lag between onset of ischemic symptoms and hospital presentation to ≤1 hour is of the utmost importance.

Since Chest pain is the most common reason somebody comes into the Emergency Department there is an acute need for a fast and reliable method for diagnosing whether the chest pain is associate with a cardiac event or not.

 

Today’s more than 50% of all patients with chest pain presenting at the emergency department have non-cardiac chest pain (NCCP) while existing solutions today are limited in their ability to associate a symptom of chest pain whether it is associated with a cardiac event.

It is even worse cases when the ECG findings of measurement are completely normal even though a heart attack has taken place. As a result, ECG does not detect two out of every three heart attacks at all or not until it is too late.

 

Cardiovascular diseases (CVDs) are the number 1 cause of death globally, taking an estimated 17.9 million lives each year from an estimated 422.7 million cases of CVD in 2015 [8]. Specifically, Coronary artery disease (CAD) is the leading cause of death in the United States; with approximately 500,000-700,000 deaths related to CAD occur each year and is also the number one cause of death in European countries.

TECHNOLOGY

CORSENS Medical developed a non-invasive device designed to measure myocardial vibrations (related to myocardial perfusion) due to changes in heart muscle contractility. The device includes a physiological data acquisition application connected to sensing patch that is attached to the chest.CORSENS Granted patentsUS 10,028,677 QUANTITATIVELY DIFFERENTIATING CARDIAC FROM NON-CARDIAC RELATED CHEST PAIN AND OTHER CARDIAC DIAGNOSTICSUS 10,172,539 DETERMINING AN AMOUNT OF REPERFUSION IN MYOCARDIUM AND ASSESSING EFFECTIVENESS OF THROMBOLYSISCorsens Medical has received clearance for a pre-marketing notification (510(k)) with the US Food and Drug Administration (FDA) for its cardiac monitor.The company received the following indications statement for the Corsens Cardiac Monitor: “The Corsens Cardiac Monitor records vibrational waveforms produced by the heart contractions and transmitted to the chest wall. Corsens Cardiac Monitor may be used as a tool to measure the timing of part of the events in the cardiac cycle for adult population.” The Corsens Cardiac Monitor is designed to detect cardiac contractility parameters via a series of acoustic, accelerometers and cardiac rhythm non-invasive sensors arrayed on the patient’s chest.

OUR TEAM

Prof. Alon Marmor
MD, PhD, co-founder, Inventor
Head of the Heart Institute, at Sieff Government Hospital, Safed, Israel. Prof. Marmor has been a principle investigator in more than 120 multicenter international clinical trials since 1988
Dr. Oded Ayzenberg
MD, Research Scientist
Cardiology specialist, is the Head of the Catheterization unit at the Kaplan Medical Center in Rehovot, Israel
Shabtay Negry
Managing Partner - CEO
Experienced C LEVEL manager with a demonstrated history of working in the Computer Software, Medical Devices, and Machine vision industries with specialization in 3D technologies and visualization.

CONTACT US

Contact Info

corsens_logo2

Contact Form
  • 8 + 23 =
Find Us on Google Map